Related Experiment Videos
Positron emission tomography as an imaging biomarker
1Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA. wweber@mednet.ucla.edu
Summary
Positron emission tomography (PET) can noninvasively assess tumor response to chemotherapy by measuring glucose metabolism. Early PET scans correlate with patient outcomes, suggesting its potential for guiding cancer treatment decisions.
Area of Science:
- Oncology
- Nuclear Medicine
- Pharmacodynamics
Background:
- Positron emission tomography (PET) offers noninvasive, quantitative insights into tumor biology.
- PET enables the study of anticancer drug pharmacokinetics and target engagement.
- PET provides early markers for assessing tumor response to therapy.
Purpose of the Study:
- To evaluate the role of PET in assessing tumor response to chemotherapy.
- To explore PET's utility in predicting patient outcomes based on metabolic changes.
- To determine PET's potential as a biomarker in early-phase clinical trials.
Main Methods:
- Utilizing PET to quantitatively measure biologic processes within tumor tissue.
- Monitoring changes in tumor glucose utilization during chemotherapy.
- Correlating early metabolic changes with patient outcomes.
Main Results:
- Significant correlation observed between changes in tumor glucose utilization and patient outcome.
- PET identified early markers of therapeutic response.
- Early identification of nonresponding tumors is feasible.
Conclusions:
- PET shows promise as a sensitive tool for assessing new cytotoxic agents in phase II studies.
- PET can facilitate personalized treatment adjustments based on tumor chemosensitivity.
- Further prospective, randomized validation is needed for clinical implementation of PET-guided chemotherapy.